{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-001712","form_type":"8-K","ticker":null,"cik":"0001183765","company_name":"Molecular Templates, Inc.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.582338+00:00","generated_at":"2026-06-04T05:12:40.661454+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Molecular Templates reports Q4 2023 net loss $3.9M; BMS termination, $9.5M placement","bullets":["Q4 2023 net loss $3.9M ($0.73/sh) vs $22.0M ($5.87/sh) in Q4 2022; revenue $7.0M vs $2.6M.","Cash $11.5M as of Dec 31, 2023; $9.5M private placement closing extends runway to Q4 2024.","Bristol-Myers Squibb terminates collaboration effective June 13, 2024; MTEM plans cost reductions.","MT-6402 shows confirmed PR (70% reduction) in HNSCC; dose expansion enrolling low PD-L1+ patients.","MT-8421 dose escalation second cohort enrolling; early evidence of Treg depletion and T-cell activation."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-001712","json":"https://secwatch.observer/filing/0001171843-24-001712.json","markdown":"https://secwatch.observer/filing/0001171843-24-001712.md","text":"https://secwatch.observer/filing/0001171843-24-001712.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1183765/000117184324001712/0001171843-24-001712-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1183765/000117184324001712/f8k_032924.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:12:40.661454+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e9b0eaae22a1bceb7c72bb0c15467d1195287ee","claim":"Molecular Templates, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On March 29, 2024, Molecular Templates, Inc. (the \"Company\") announced its financial results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1183765/000117184324001712/0001171843-24-001712-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}